Evidence map›Paper›PMID 42179795›Full record

ArticleJournal of Cancer2026

Yi-Chung Chien, Guo-Wei Wu, Yu-Heng Lin, Jia-Yan Wu, Yung-Luen Yu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of Cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yi-Chung ChienDepartment of Physiology, School of Medicine, China Medical University, Taichung 406040, Taiwan.
Guo-Wei WuCenter for Molecular Medicine, China Medical University Hospital, Taichung 404327, Taiwan.
Yu-Heng LinGraduate Institute of Biomedical Sciences, China Medical University, Taichung 406040, Taiwan.
Jia-Yan WuCenter for Molecular Medicine, China Medical University Hospital, Taichung 404327, Taiwan.
Yung-Luen YuCenter for Molecular Medicine, China Medical University Hospital, Taichung 404327, Taiwan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Triple-negative breast cancer (TNBC) is among the most aggressive subtypes of breast cancer, frequently characterized by invasive growth, metastasis, and poor clinical outcomes. Brain metastasis, commonly observed in TNBC patients, significantly worsens prognosis and survival rates. Current therapeutic strategies for TNBC brain metastases remain limited and largely ineffective. Mutant p53, common in TNBC, promotes malignancy and metastasis. MDA-MB-231 cells and their brain metastatic variant (MDA-MB-231-Br) harbor a p53 R280K mutation.

Indexed as

brain metastasisGanoderma lucidump53triple-negative breast cancer

Identifiers

PMID42179795
PMCPMC13189825

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.